BR112020015821A2 - Composições e métodos para induzir sinalização de proteína 16 contendo motivo tripartido - Google Patents

Composições e métodos para induzir sinalização de proteína 16 contendo motivo tripartido Download PDF

Info

Publication number
BR112020015821A2
BR112020015821A2 BR112020015821-6A BR112020015821A BR112020015821A2 BR 112020015821 A2 BR112020015821 A2 BR 112020015821A2 BR 112020015821 A BR112020015821 A BR 112020015821A BR 112020015821 A2 BR112020015821 A2 BR 112020015821A2
Authority
BR
Brazil
Prior art keywords
cancer
nucleic acid
fact
cell
pamp
Prior art date
Application number
BR112020015821-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael J. Gale Jr.
Original Assignee
University Of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington filed Critical University Of Washington
Publication of BR112020015821A2 publication Critical patent/BR112020015821A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112020015821-6A 2018-02-02 2019-02-01 Composições e métodos para induzir sinalização de proteína 16 contendo motivo tripartido BR112020015821A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625623P 2018-02-02 2018-02-02
US62/625,623 2018-02-02
PCT/US2019/016413 WO2019152884A1 (en) 2018-02-02 2019-02-01 Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling

Publications (1)

Publication Number Publication Date
BR112020015821A2 true BR112020015821A2 (pt) 2021-03-09

Family

ID=67479930

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020015821-6A BR112020015821A2 (pt) 2018-02-02 2019-02-01 Composições e métodos para induzir sinalização de proteína 16 contendo motivo tripartido

Country Status (9)

Country Link
US (1) US20210046168A1 (https=)
EP (1) EP3746088B1 (https=)
JP (1) JP7409612B2 (https=)
KR (1) KR102828978B1 (https=)
CN (1) CN111836623A (https=)
AU (1) AU2019215191B2 (https=)
BR (1) BR112020015821A2 (https=)
RU (1) RU2020128838A (https=)
WO (1) WO2019152884A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
WO2021067480A1 (en) * 2019-10-02 2021-04-08 University Of Washington Compositions and methods for treatment of hepatitis b virus infection
WO2021097347A1 (en) * 2019-11-15 2021-05-20 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
KR20220156933A (ko) 2020-03-23 2022-11-28 에이치디티 바이오 코포레이션 Rna의 전달을 위한 조성물 및 방법
EP4112665A4 (en) * 2020-03-27 2024-04-10 Mitsui Chemicals, Inc. LIGHT-CURING COMPOSITION, CURED PRODUCT AND DENTAL PRODUCT
AU2022302143A1 (en) 2021-07-02 2024-01-18 Yale University Compositions and methods for treating cancers
EP4395832A1 (en) 2021-08-31 2024-07-10 Yale University Compositions and methods for treating cancers
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
JP2024535354A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
WO2023048760A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Rna vaccines against infectious diseases
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
US20230303719A1 (en) 2022-03-03 2023-09-28 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078595A2 (en) * 2002-03-15 2003-09-25 Astral, Inc. Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Eduardo Nowill Alexandre agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
US9775894B2 (en) 2013-07-09 2017-10-03 University Of Washington Through Its Center For Commercialization Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
WO2016179034A2 (en) * 2015-05-01 2016-11-10 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
MA44252A (fr) * 2016-02-16 2018-12-26 Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation

Also Published As

Publication number Publication date
EP3746088B1 (en) 2024-07-10
CN111836623A (zh) 2020-10-27
KR102828978B1 (ko) 2025-07-02
AU2019215191A1 (en) 2020-09-17
JP7409612B2 (ja) 2024-01-09
EP3746088A4 (en) 2023-02-22
EP3746088A1 (en) 2020-12-09
KR20200116976A (ko) 2020-10-13
EP3746088C0 (en) 2024-07-10
WO2019152884A1 (en) 2019-08-08
AU2019215191B2 (en) 2025-08-14
US20210046168A1 (en) 2021-02-18
JP2021512123A (ja) 2021-05-13
RU2020128838A (ru) 2022-03-03

Similar Documents

Publication Publication Date Title
BR112020015821A2 (pt) Composições e métodos para induzir sinalização de proteína 16 contendo motivo tripartido
US11708396B2 (en) Signal-sensor polynucleotides for the alteration of cellular phenotypes
US20240024422A1 (en) Polynucleotides encoding interleukin-12 (il12) and uses thereof
AU2017266948B2 (en) Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
Harris et al. Wild-type p53 suppresses transcription of the human O 6-methylguanine-DNA methyltransferase gene
Bavelloni et al. AKT‐dependent phosphorylation of the adenosine deaminases ADAR‐1 and‐2 inhibits deaminase activity
US20240366736A1 (en) Method for managing pain
Wang et al. Cancer‐derived IgG involved in cisplatin resistance through PTP‐BAS/Src/PDK1/AKT signaling pathway
Nandi et al. CD155: a key receptor playing diversified roles
CN109609644B (zh) Pax3-fkhr和acta1基因在预防、治疗横纹肌肉瘤中的用途
Li et al. A role for mitogen‐activated protein kinase and Ets‐1 in the induction of interleukin‐10 transcription by human immunodeficiency virus‐1 Tat
US20060052322A1 (en) Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
CN114042160A (zh) Ctd-2256p15.2及其编码微肽作为靶点在开发肿瘤治疗药物中的应用
JP2012505233A (ja) マイクロｒｎａ−１９６の過剰発現によるｃ型肝炎ウイルス感染の治療
Arora et al. Transcriptome profiling of canine parvovirus 2 nonstructural gene 1 (CPV2. NS1) transfected 4T1 mice mammary tumor cells to elucidate its oncolytic effects
JP2004180540A (ja) 哺乳動物のＴｏｌｌ様受容体３に結合する新規アダプタータンパク質およびその遺伝子
JP2015515485A (ja) Ｒｎａリガーゼ複合体メンバーとしてのアーキアーゼ
WO2008066744A2 (en) Methods and compositions for treating and preventing spinal cord injury and other neuronal disease or injury
WO2023077133A2 (en) Controlling homeostatic regulatory circuitry in hypothalamus
KR20150130669A (ko) Ａｂｉ1 발현 또는 활성 억제제를 포함하는 Ｃ형 간염 예방 및 치료용 약제학적 조성물
Xu et al. Construction of a recombinant pIRES2-EGFP-ARTS plasmid and its effect on LX-2 cells
CN121130086A (zh) Hs2st1抑制剂在制备治疗egfr-tki耐药肿瘤的药物中的应用
WO2021034634A2 (en) Compositions and methods utilizing a novel human foxo3 isoform
WO2020075836A1 (ja) Ｂ型肝炎ウイルス複製阻害剤及びそれを含むｂ型肝炎治療用医薬組成物
HK40054624B (zh) 用於制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]